-+ 0.00%
-+ 0.00%
-+ 0.00%

Medicus Pharma submits IND to Abu Dhabi health regulator for Teverelix endometriosis trial

PUBT·06/11/2026 11:30:58
Listen to the news
Medicus Pharma submits IND to Abu Dhabi health regulator for Teverelix endometriosis trial
  • Medicus Pharma submitted an IND application to Abu Dhabi’s Department of Health for its PRECISION-E2 Phase 2a Teverelix study in endometriosis.
  • The genomics-enabled trial plans to enroll about 84 women in the UAE, leveraging participants in the Emirati Genome Program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110730PRIMZONEFULLFEED9735346) on June 11, 2026, and is solely responsible for the information contained therein.